M. Gargallo

Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant

M. Rubio, M. Gargallo, Ana Isabel Millán, 2007, Public Health Nutrition.

Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings

M. Sampedro-Núñez, M. Marazuela, A. Ramos-Leví, 2018, Front. Endocrinol..

[Risk factors of persistent disease at 5 years from diagnosis in differentiated thyroid cancer: study of 63 patients].

M. A. Tapia, M. Gargallo, C. Familiar, 2009, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity

E. Blázquez, O. Vincent, E. Delgado-Álvarez, 2007, Diabetologia.

Abnormally low HbA1c secondary to hemoglobin J-Baltimore [beta 16(A13) Gly-->Asp]. Family study.

M. Gargallo, A. Villegas, F. González, 2010, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity.

A. Martí, F. Casanueva, F. Tinahones, 2017 .

Differential Effects of HNF-1α Mutations Associated with Familial Young-Onset Diabetes on Target Gene Regulation

M. Gargallo, M. Navas, V. Andía, 2011, Molecular medicine.

Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19

D. Orozco-Beltrán, R. Gómez-Huelgas, J. Merino-Torres, 2022, Endocrinología, Diabetes y Nutrición (English ed.).

Familial transmission of a duplication‐deficiency X chromosome associated with partial Turner syndrome

M. Gargallo, J. A. Abrisqueta, V. Aller, 1995, Clinical genetics.